Erratum: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

被引：0
|
作者：
I Breitkreutz
M S Raab
S Vallet
T Hideshima
N Raje
C Mitsiades
D Chauhan
Y Okawa
N C Munshi
P G Richardson
K C Anderson
机构：
来源：
Leukemia | 2008年 / 22卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Correction to: Leukemia (2008) 22, 1925–1932; doi:10.1038/leu.2008.174; published online 3 July 2008 Owing to a typesetting error, Figure 2b of the above article was published incorrectly. The correct figure is reproduced here. The publisher apologizes for this error and any inconvenience it may have caused.
引用
收藏
页码：1973 / 1973
相关论文
共 50 条
  • [21] Biochemical bone markers in patients with multiple myeloma
    Nawawi, H
    Samson, D
    Apperley, J
    Girgis, S
    CLINICA CHIMICA ACTA, 1996, 253 (1-2) : 61 - 77
  • [22] Assessment of bone markers in multiple myeloma.
    Malati, T
    Yadagiri, B
    CLINICAL CHEMISTRY, 2003, 49 (06) : A102 - A103
  • [23] Biochemical markers of bone metabolism in multiple myeloma
    Terpos, E
    CANCER TREATMENT REVIEWS, 2006, 32 : 15 - 19
  • [24] The effects of proteasome inhibitors on bone remodeling in multiple myeloma
    Zangari, Maurizio
    Suva, Larry J.
    BONE, 2016, 86 : 131 - 138
  • [25] Lenalidomide data in multiple myeloma patients demonstrate impressive survival benefit
    不详
    ONCOLOGY-NEW YORK, 2007, 21 (09): : 1143 - 1143
  • [26] Erratum to: Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
    Shinsuke Iida
    Takaaki Chou
    Shinichiro Okamoto
    Hirokazu Nagai
    Kiyohiko Hatake
    Hirokazu Murakami
    Toshiyuki Takagi
    Kazuyuki Shimizu
    Henry Lau
    Kenichi Takeshita
    Masaaki Takatoku
    Tomomitsu Hotta
    International Journal of Hematology, 2010, 92 (1) : 127 - 128
  • [27] Chrysin alleviates alteration of bone-remodeling markers in ovariectomized rats and exhibits estrogen-like activity in silico
    Ibrahim, Sadiyat O.
    Mada, Sanusi B.
    Abarshi, Musa M.
    Tanko, Muhammad S.
    Babangida, Sanusi
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2021, 40 (12_SUPPL) : S125 - S136
  • [28] Genetic markers as prognostic factors in multiple myeloma
    Conte L, Guillermo
    Braggio, Esteban
    Figueroa, Gaston
    Fonseca, Rafael
    REVISTA MEDICA DE CHILE, 2009, 137 (04) : 552 - 558
  • [29] Bone Health and Survival in Women With Multiple Myeloma
    Rosko, Ashley E.
    Hade, Erinn M.
    Li, Wenjun
    Ing, Steven
    Jackson, Rebecca D.
    Paskett, Electra D.
    Naughton, Michelle J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (09): : 597 - +
  • [30] Risk factors for neutropenia with lenalidomide plus dexamethasone therapy for multiple myeloma
    Mitani, Y.
    Usami, E.
    Kimura, M.
    Nakao, T.
    Okada, K.
    Matsuoka, T.
    Kokuryou, T.
    Yoshimura, T.
    Yamakawa, M.
    PHARMAZIE, 2016, 71 (06): : 349 - 351
12345